“Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies”, J of Skin, vol. 6, no. 2, p. s28, Mar. 2022, doi: 10.25251/skin.6.supp.28.